/NOT FOR DISTRIBUTION TO UNITED STATES NEWS SERVICES OR BROADCASTING IN THE UNITED STATES/

TORONTO, November 23, 2022 /CNW/ – Cliffside Capital Ltd. (“Cliff” or the “Company“) (TSXV: CEP) is pleased to announce its financial results for the third quarter ended September 30, 2022. The Company has pursued its long-term strategy of disciplined growth and announces:

• 37% increase in net financial receivables $135.7 million like a September 30, 2021

• to a record of $185.9 million like a September 30, 2022;

• $14.0 million net interest income, an increase of 51.1% over the same period last year;

• $7.2 million net financial income before credit losses and excluding mark-to-market gains on derivative financial instruments, an increase of 38.5% compared to the same period of the previous year; and

• $0.4 million the net loss before income taxes, due to the amortization of financing costs in one of its partnerships, an increase in net interest expense consistent with the growth of its financial receivables in the current rate environment and an increase in its provision for credit losses. Given the overall challenging global business environment, continued high inflation, growth in financial claims and the prospect of further interest rate hikes, the Company’s provision for credit losses increased of $6 million compared to the same period of the previous year when macroeconomic conditions were more favourable.

Subsequent to the quarter, the Company also declared a quarterly cash dividend on the outstanding common shares of $0.0025 per ordinary share ($0.01 on an annualized basis), which was paid on November 10, 2022. Each of these dividends is qualified as an “eligible” dividend as defined in the income tax law (Canada). Dividends were subject to customary Canadian withholding tax for non-resident shareholders of Canada.

Company Update

The Company’s partnerships continue to benefit from access to market financing from various Canadian lenders for any purchase of new auto loans receivable. An installation was renewed in October 2022 for $100 milliona $25 million increase. The financing facility used for CAR LP I will not be renewed beyond January 2023. Consistent with the original loan terms and market practice for similar loan facilities, all cash flow from the partnership will first repay the primary lender and then go to the mezzanine lender, with the remaining balance going to the partnership’s equity.

The story continues

Global Macroeconomic Challenges

Recent and ongoing global macroeconomic events, including global supply chain delays, war in Ukraine, rising global inflation along with the expectation of a continued inflationary environment coupled with rising interest rates has led alternative and non-bank financial companies, such as Cliffside, to face a challenging environment in which to raise equity for growth. Although Cliffside retains access to sources of financing, management believes that these recent macroeconomic challenges could adversely affect the Company’s ability to raise new equity capital to fund its future growth. Consequently, the recent strong growth pattern that the Company has experienced may be difficult to sustain. Management and the Board of Directors are actively monitoring and reviewing the options available to adapt to the current environment and will continue to explore all opportunities available to the Company.

Further information on Cliffside’s financial results is available at www.cliffsidecapital.ca.

About Cliffside

Cliffside is focused on investing in strategic partnerships with parties that have specialized expertise and proven experience in originating and servicing loans and similar types of financial assets. Cliffside’s strategy is to generate income as an investor, providing its shareholders with the opportunity to invest in the growing alternative lending industry with the potential for attractive returns and minimal operational risk while achieving a reliable total return. For more information, see Cliffside’s filings on SEDAR at www.sedar.com.

CAUTION REGARDING FORWARD-LOOKING INFORMATION: This press release contains certain “forward-looking statements” under applicable Canadian securities laws. Forward-looking statements include, but are not limited to, statements regarding the business and operations of Cliffside and its partnerships, statements regarding the company’s ability to raise equity in the future, statements regarding renewals expected terms of certain debt financing facilities, the expected terms of such renewals and the intended use of proceeds, and management’s ability to protect and effectively grow the Company’s business in light of recent and In progress. Forward-looking statements are necessarily based on a number of estimates and assumptions which, while believed to be reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ. and future events differ materially from those expressed or implied. by such forward-looking statements. These factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the results of operations; potential for conflicts of interest; the availability of suitable financial claims that can be purchased by the Company’s limited partnerships under existing financing facilities; and the volatility of the price and volume of the Common Shares. There can be no assurance that such statements will prove to be accurate or complete, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Cliffside disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Cliffside Capital Ltd.

View original content: http://www.newswire.ca/en/releases/archive/November2022/23/c1627.html

-Agreement Provides Flexible Funding on Path to NDA Submission for PAX-101-

TARRYTOWN, NY, Nov. 17, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic (“APT”) drug therapies for the treatment of disorders with refractory neurological symptoms, today announced that the Company has entered into a purchase agreement and a recording rights agreement (together, the “Agreement”) for up to $20 million dollars with Lincoln Park Capital Fund, LLC (“Lincoln Park”).

Under the terms and conditions of the agreement, including the effectiveness of a related registration statement, the company has the right, but not the obligation, to sell up to $20 million of its stock. at Lincoln Park over a 30-month period, subject to certain limitations. Any common stock sold to Lincoln Park will take place at a purchase price which is determined by the prevailing market prices at the time of each sale with no upper limit than the price Lincoln Park can pay to purchase the common stock. The agreement contains no restrictions on the use of any of the products and there are no financial commitments, participation rights, rights of first refusal or penalties. There are no warrants, derivatives, financial or trading covenants associated with the Agreement and Lincoln Park has agreed not to cause or engage in any direct or indirect short selling or hedging of ordinary shares of the Company. The Company has issued common stock to Lincoln Park in consideration for Lincoln Park’s commitment to purchase the Company’s common stock under the Agreement. The Company intends to use the net proceeds from the sale of its common stock under the Agreement for working capital and general corporate purposes to support its growth.

Howard Weisman, Chief Executive Officer of PaxMedica, said, “This funding provides us with additional flexibility as we move towards completing intravenous suramin manufacturing validation in preparation for late 2023 NDA submission for the human african trypanosomiasis (brucei rhodesiense). The NDA, once submitted, should also trigger a Priority Review Voucher (PRV) request which the company plans to monetize upon receipt.

The story continues

Further details regarding the agreement and this transaction will be contained in the current report on Form 8-K that the company intends to file with the Securities and Exchange Commission (the “SEC”).

This press release does not constitute an offer to sell or a solicitation of an offer to buy common stock, and there will be no sale of common stock in any state or jurisdiction in which such offer, solicitation or sale be unlawful prior to registration or qualification under the securities laws of such state or other jurisdiction.

About PaxMedica
PaxMedica is a clinical-stage biopharmaceutical company focused on the development of anti-purinergic drug therapies (“APTs”) for the treatment of disorders with refractory neurological symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorders (“APTs”). ASD”), myalgic encephalomyelitis. /Chronic Fatigue Syndrome (“ME/CFS”), a debilitating physical and cognitive disorder believed to be viral in origin and now increasing in incidence worldwide due to the long-term effects of SARS-CoV -2 (“COVID-19”). A major focus of PaxMedica is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and advancing the clinical understanding of the use of this agent against other disorders such as ME/CFS and Long COVID-19 Syndrome, a clinical diagnosis in people who have been previously infected with COVID-19.

Forward-looking statements
This press release contains “forward-looking statements”. Forward-looking statements reflect our current view of future events. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections regarding future events that the Company believes could affect its financial condition, results of operations, business strategy and financial needs. Investors may identify these forward-looking statements by words or phrases such as “may”, “will”, “could”, “expect”, “anticipate”, “aim”, “estimate”, “have the intention to”, “plan”, “believe”, “is/are likely to”, “propose”, “potential”, “continue” or similar expressions. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will prove to be correct, and the Company cautions investors that actual results may differ materially from anticipated results and encourages investors to discuss other factors that could affect its future results in the company’s most recent registration statement and quarterly reports and other filings with the United States Securities and Exchange Commission.

contacts:

ir@paxmedica.com

Stephanie Prince
PCG Notice
sprince@pcgadvisory.com
(646) 863-6341

There are a few key trends to look out for if we want to identify the next multi-bagger. Among other things, we will want to see two things; first, growth come back on capital employed (ROCE) and on the other hand, an expansion of the amount capital employed. Simply put, these types of businesses are slot machines, meaning they continually reinvest their profits at ever-higher rates of return. However, after investigating AWC Berhad (KLSE:AWC), we don’t think current trends fit the mold of a multi-bagger.

Understanding return on capital employed (ROCE)

For those unaware, ROCE is a measure of a company’s annual pre-tax profit (yield), relative to the capital employed in the business. The formula for this calculation on AWC Berhad is:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets – Current Liabilities)

0.16 = RM46m ÷ (RM412m – RM117m) (Based on the last twelve months to June 2022).

Thereby, AWC Berhad has a ROCE of 16%. In absolute terms, that’s a decent return, but compared to the construction industry average of 5.1%, it’s much better.

See our latest analysis for AWC Berhad

Above, you can see how AWC Berhad’s current ROCE compares to its past returns on capital, but you can’t say anything about the past. If you want, you can check out analyst forecasts covering AWC Berhad here for free.

What the ROCE trend can tell us

On the surface, the ROCE trend at AWC Berhad does not inspire confidence. To be more specific, ROCE has fallen by 22% over the past five years. However, it looks like AWC Berhad could reinvest for long-term growth because while capital employed has increased, the company’s sales have not changed much over the past 12 months. It may take some time before the company begins to see a change in the income from these investments.

On a related note, AWC Berhad reduced its current liabilities to 28% of total assets. This could partly explain why ROCE fell. Additionally, it may reduce some aspects of risk to the business, as the business’s suppliers or short-term creditors now fund less of its operations. Some would argue that this reduces the company’s effectiveness in generating a return on investment, as it now funds more of the operations with its own money.

The story continues

The essentials of AWC Berhad’s ROCE

In summary, AWC Berhad is reinvesting funds into the business for growth, but unfortunately, it appears sales haven’t grown much yet. Given that the stock has fallen 53% in the past five years, investors may not be too optimistic that this trend is improving either. Overall, we’re not overly inspired by the underlying trends and think there may be a better chance of finding a multi-bagger elsewhere.

AWC Berhad comes with some risks though, and we spotted 2 warning signs for AWC Berhad that might interest you.

Although AWC Berhad does not generate the highest yield, check out this free list of companies that achieve high returns on equity with strong balance sheets.

Feedback on this article? Concerned about content? Get in touch with us directly. You can also email the editorial team (at) Simplywallst.com.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.

Join a Paid User Research Session
You will receive a $30 Amazon Gift Card for 1 hour of your time while helping us create better investment tools for individual investors like you. register here

The Tata Group is in talks with banks to acquire working capital loans of around Rs 15,000 crore for Air India, the airline it bought from the government last year and is making a valiant push to revive. , reported The economic period.

According to a person familiar with the matter, the funds will be used to cover day-to-day flight operations and losses, restore the fleet, pay for aircraft rentals and overhaul computer systems.

According to another source, the loan will have a term of three years with an annual reset of between 7.5 and 8%.

Last year, State Bank of India (SBI), HDFC Bank and Bank of Baroda extended an unrated and unsecured loan of Rs 23,000 crore to Talace, a Tata Sons company that won the bid of Air India, at a rate of 4.25%. . At the end of January, the loan must be renewed.

According to a bank official, rising interest rates and lack of liquidity in the system will increase borrowing costs. The Reserve Bank of India’s website lists 6.91% as the threshold for 364-day Treasury bills.

Tata Sons, through Talace, won Air India’s bid for Rs 18,000 crore in October last year. Some 69 years after the government nationalized the airline in August 1953, it took ownership of the carrier in January this year.

Partnership with RC Capital will support continued growth and capacity expansion

ST. PETERSBURG, Fla. and CINCINNATI and RALEIGH, North Carolina, Oct. 25, 2022 /PRNewswire/ — RC Capital, a healthcare-focused private equity firm that invests growth capital in innovative healthcare companies, today announced the closing of a growth and recapitalization investment in Cognitive Research Corporation (“CRC” or the “Company”), a leading, full-service, dedicated contract research organization (CRO) therapy, specializing in the area of ​​the central nervous system (CNS).

RCC invested growth capital and partnered with management to acquire a majority stake in St. Petersburg, Florida-based CRC. The transaction allows CRC to accelerate its business development efforts, broaden the scope of its services to better serve its growing customer base and strengthen its global presence, all to meet the incredible demand that the Company experienced over the past few years. Founders, Dr. Tom Hochadel and Dr. Gary Kay, along with newly appointed CEO, CG Gillooly, and other members of management will retain a significant ownership position in the company.

Founded in 2006 by Dr. Tom Hochadel, Dr. Gary Kay, Dr. Thomas Crook and Steven Horohonich, CRC is a full-service contract research organization and technology company specializing in central nervous system product development ( SNC) for the pharmaceutical, nutraceutical, biotechnology and medical device industries. CRC works with sponsors, specialist clinical trial sites and CNS experts to bring new drugs to market through rigorous testing.

“RCC’s expertise and network will bring additional resources and business development opportunities to CRC, and this growth-focused transaction will help us accelerate the execution of our growing backlog,” said co-founder Tom Hochadel. . “We are delighted to partner with RC Capital to help CRC leverage the massive need in the pharmaceutical and biotech market for specialized clinical trial partners to help bring safe and effective CNS therapies to market,” adds the co. -founder Gary Kay.

“We are delighted to partner with RC Capital to implement a number of strategic initiatives, including expanding our services, operations and key recruiting in the United States and globally,” said CG “Chip” Gillooly, CEO. “We have met with many leading private equity firms that operate in the life science services space and chose RC Capital because of their impressive track record of successfully working with the management of healthcare companies. in the growth phase to better meet the needs of the markets they serve.We look forward to working with the RCC team to continue to build on the strong 17-year legacy established by the founders of CRC Pharmaceutical sponsors, small pharma and biotech sponsors in particular, crave a CRO partner who understands the unique needs and nuances of their business model and can translate that into world-class customer service and trial guidance. further to build a new CRO era.

“RC Capital seeks to partner with the founders and management teams of high-growth companies like CRC that deliver lasting value to the life sciences and healthcare industries and ultimately better results. for patient health,” said Rob Heimann, managing partner at RC Capital. “With a 17-year operating history, hundreds of trials managed in over 30 indications, and dozens of CNS NDA submissions, Tom Hochadel, Gary Kay and the CRC team have developed an experience a rare and important domain in the successful execution of clinical trials for pharmaceutical sponsors striving to bring new SNC products to market.We look forward to working with Chip and the entire CRC team in their next phase of growth.

“We are in a new era of CNS biotech innovation, and it has never been more needed,” says Patrick Dunnigan, Partner at RC Capital. “After decades of limited innovation by the pharmaceutical industry, significant advances have recently been made in understanding the structure and functions of the central nervous system, leading to significant investments in the discovery of new drugs to treatment of CNS disorders. Neurodegenerative disorders and mental health disorders, which have a significant impact on society, have been the focus of particular attention. We look forward to helping advance CRC’s mission to helping our clients bring important and innovative therapies to market for the benefit of patients around the world.

Heimann and Dunnigan will join the CRC Board of Directors. In addition, CRC has appointed Jeff Williams as Executive Chairman of the Board. Jeff is a seasoned healthcare executive. He previously served as CEO of Mindpath Care Centers, a behavioral health company, and founder and CEO of Clinipace, a biotechnology-focused CRO.

Financial terms of the transaction were not disclosed. McGuireWoods LLP provided legal advice to the RCC and Wyrick, Robbins, Yates and Ponton LLP provided legal advice to the CRC.

About the Cognitive Research Society

Cognitive Research Corporation’s mission is to support innovative companies that develop new drugs and therapies to improve mental health and neurological disorders. As a leading clinical research organization (CRO) and cognitive assessment technology company in neuroscience, CRC works with sponsors, specialist clinical trial sites and CNS experts to push new drugs through rigorous testing to support FDA submissions and eventual market introduction.

For more information, visit www.cogres.com.

About RC Capital

RC Capital (RCC) is a healthcare-focused growth capital firm that strives to partner with high-potential healthcare companies and leaders. We are committed to investing in the good side of healthcare, building businesses that enable clinicians to improve the delivery of care and advance experiences and outcomes for patients around the world. We seek to be a business partner first and a capital provider second, leveraging a network of deep healthcare relationships built over our 28-year operating history. For more information, please visit www.rccapital.com.

Contact person: – RC Capital

Britney Hamberg

bh@rccf.com

See original content to download multimedia: https://www.prnewswire.com/news-releases/rc-capital-completes-growth-recapitalization-of-cns-focused-cro-cognitive-research-corporation-301658847.html

SOURCE RC Capital

The University of Manchester is launching the public phase of a $45 million fundraising campaign, the university announced on Saturday. Funding raised through ‘Manchester Bold: The Future is Ours’ will support a variety of projects, including improvements to Winger Hall and Funderburg Library and a new wellness and sports performance centre.

Manchester have announced the public phase as part of their Homecoming celebration. The university says it has already raised $36.8 million in donations and pledges during its “silent” phase.

“We anticipate the future and embrace it with open arms,” ​​Chairman Dave McFadden said in written remarks. “We see opportunities on the horizon and we are claiming them. Manchester Bold means we drive our mission and encourage students to discover the best in themselves.

The campaign allows donors to provide support in six different areas.

The university aims to raise $6.5 million for its New Initiatives Fund, which has in the past been used to launch traditional and accelerated nursing programs, as well as the Spartan Pride Marching Band.

A total of $5 million will be used for renovations to Otho Winger Hall, which was originally built in 1952. Manchester says the improvements will help students “develop their relationship with the arts and study subjects contemporaries such as graphic design and music technology”.

The university plans to use $6 million from the campaign to create the Sports Performance and Wellness Center, a multi-purpose indoor wellness facility. The center will provide more space and equipment for Manchester NCAA Division III student-athletes, as well as participants in intramural and recreational sports.

The Manchester Fund will receive $11 million from the campaign. The fund provides additional financial aid to students who have above-average financial need or are experiencing cuts in government aid. It also pays for repairs to college buildings, technology upgrades, and covers travel expenses when students need to travel to present lectures or when sports teams advance in tournaments, among other things.

The campaign will also provide $8 million to the university’s endowment fund. Another $5.5 million will be used for upgrades to the Funderburg library, although specific plans have not been described.

“This is an exciting time in the history of this institution,” said Melanie Harmon, vice president for advancement. “Our donors have been there for us since day one, and I’m confident they will be there for us with Manchester Bold. The need has never been greater and now is the time.

The campaign is led by Randy Brown, a 1987 Manchester graduate and managing partner of Barnes & Thornburg LLP in Fort Wayne.

We’ll have more information on President McFadden’s campaign in Monday afternoon’s INside Edge newsletter.

In the current economic environment, cash flow and the availability of cash have become kings. These economic circumstances are causing many companies to reassess their capital structure, even those with strong balance sheets. Private companies exploring options for raising capital have two main decisions to make: (1) what type of security to offer and (2) what method to use to comply with securities laws.

1. Capital structure options: what security to offer

Rising interest rates make raising equity or other similar solutions more attractive to founders and business owners looking to fund their growth. The table below illustrates capital structure options ranging from senior debt (much like a typical secured bank loan) to common stock.

CAPITAL STRUCTURE	senior debt	Revolving Loans and Term Loans Fully secured by tangible assets Short-term in nature with strict amortization Requires personal guarantees from the founders
	Mezzanine debt	Usually 2n/a Senior Term Loans Requires positive cash flow Long-term capital with limited or no amortization Flexible and personalized agreements Typically includes warrants, but is less dilutive than equity
	Hybrid financing (e.g. convertible debt, convertible equity)	Date of conversion into preferred shares Interest rate that can be repaid upon conversion Investors convert to common stock once the company goes public
	Simple Agreement for Future Fairness (SAFE Rating)	Considered more founder-friendly than convertible debt and closer to equity than convertible debt Outstanding indefinitely until next equity financing (“NEF”) No maturity date/conversion date Investors only receive the right to convert shares at a lower price than the NEF
	Favorite stock	Typically includes liquidation, conversion, call and voting provisions Usually carries a dividend, but no amortization
	Common equity	Highly dilutive emissions generally affect control

2. Methods to raise private capital

After deciding which security to offer, issuers typically evaluate four main factors to determine the type of securities offering to pursue: (1) the dollar value of the offer, (2) whether the offer will require general solicitation to be successful, (3) whether funds can only be raised from accredited investors, either through the friends and family of the issuer or through the contacts of a broker or crowdfunding platform, and (4) what type of SEC filing is required.

After the changes made by the JOBS law and the adoption of the CF regulations, the main difference between the methods of exempt offer is
whether the offer permits general solicitation. It is also the most influential factor in terms of the risk that the offer represents for the issuer. General solicitation offers require additional compliance efforts. Below is a summary of bid waivers based on the above factors. Although there are other things to consider, such as whether securities will be restricted after the offering, or what requirements apply (for example“bad actor” disqualifications apply or audited financial statements must be provided), the bulk of evaluating the appropriate offer often comes down to these factors for medium and small businesses.

Capital Raising Methods and Exemptions Available

	Nature of exemption
Offer a limit of $ in a 12 month period	Prohibits general solicitation	Allows general solicitation	Accredited investors only	SEC Filing Required
None	Reg. D Rule 506(b)		Unlimited accredited investors, limited to 35 sophisticated investors in a 90 day period	Yes. Form D
None	§4(a)(2) Transactions must not involve any public offering. Typically involve institutional buyers performing due diligence who do not need the protection of the 1933 Act. SEC vs. Ralston Purina Co.		Nope	No, but state registration requirements are not preempted by federal law.
None		Reg D, Rule 506(c)	Only Accredited Investors and Reasonable Due Diligence Steps Required	Yes. Form D
$5 million		FC regulations	Non-accredited investors subject to investment limits based on income and net worth. Requires the use of a regulated crowdfunding platform, such as Dealmaker, Republic.com	Yes. Form C (including 2-year financial statements, certified, revised or audited, as required)
Individual state limits typically $1-5 million		Intrastate Rules: §3(a)(11), Rule 147, Rule 147A	Current requirements for the issuer and the investor	No SEC filings, but states vary in notice/registration filing requirements
$10 million		Rule 504	Applicable requirements for issuer and investors	Yes
$20 million		Reg A, Level 1	None	Yes
$75 million		Reg A, Level 2	Non-accredited investors subject to investment limits, unless the issuer is listed	Yes

Securities Filings Required: State or Federal

The vast majority of waivers require the filing of a securities filing with state and/or federal regulatory authorities (e.g., Form D, Form C, Form 1-A, or state filings) and the preparation of subscription agreements and disclosure documents. Many offerings also require audited financial statements and the issuance of an offering circular to each investor. These documents should be prepared by a securities lawyer.

The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

POPULAR ARTICLES ON: US Corporate/Commercial Law

Australia has rescinded a previous government’s recognition of West Jerusalem as Israel’s capital, the foreign minister said on Tuesday.

The cabinet of the center-left Labor Party government agreed to re-recognize Tel Aviv as the capital and reaffirmed that the status of Jerusalem must be resolved within the framework of peace negotiations between Israel and the Palestinians, the minister said of Foreign Affairs Penny Wong.

Australia remains committed to a two-party solution to the conflict between Israelis and Palestinians, and we will not support an approach that undermines that prospect, Wong said.

Former Conservative Prime Minister Scott Morrison formally recognized West Jerusalem as Israel’s capital in December 2018, although the Australian embassy remained in Tel Aviv.

The move follows then-US President Donald Trump’s decision to move the US Embassy from Tel Aviv to Jerusalem. President Joe Biden has retained the embassy in Jerusalem as the United States withdraws from its once intense mediation between the Israelis and the Palestinians, who have not held substantive peace talks in more than a decade.

Wong described Morrison’s move as internationally offbeat and a cynical attempt to win a by-election in a Sydney locality with a large Jewish population.

Morrison’s Liberal Party fielded Jewish candidate Dave Sharma who was defeated in the by-election but won the seat in the next general election.

The Morrison government was removed from office in May after nine years in power.

(Only the title and image of this report may have been edited by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Finding a business that has the potential to grow significantly isn’t easy, but it is possible if we look at a few key financial metrics. A common approach is to try to find a company with Return on capital employed (ROCE) which is increasing, in line with growth amount capital employed. This shows us that it is a compounding machine, capable of continuously reinvesting its profits back into the business and generating higher returns. In light of this, when we looked Cobram Estate Olives (ASX:CBO) and its ROCE trend, we weren’t exactly thrilled.

Return on capital employed (ROCE): what is it?

Just to clarify if you’re not sure, ROCE is a measure of the pre-tax income (as a percentage) that a business earns on the capital invested in its business. To calculate this metric for Cobram Estate Olives, here is the formula:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets – Current Liabilities)

0.013 = AU$6.5 million ÷ (AUD$551 million – AU$39 million) (Based on the last twelve months to June 2022).

Thereby, Cobram Estate Olives has a ROCE of 1.3%. Ultimately, it’s a poor performer and it underperforms the food industry average by 5.0%.

Check out our latest analysis for Cobram Estate Olives

Above, you can see how Cobram Estate Olives’ current ROCE compares to its past returns on capital, but you can’t say anything about the past. If you wish, you can view analyst forecasts covering Cobram Estate Olives here for free.

The ROCE trend

On the surface, the ROCE trend at Cobram Estate Olives does not inspire confidence. About five years ago, the return on capital was 8.8%, but since then it has fallen to 1.3%. However, it looks like Cobram Estate Olives could reinvest for long-term growth because while capital employed has increased, the company’s sales have not changed much over the past 12 months. It may take some time before the company begins to see a change in the income from these investments.

The story continues

Our take on the ROCE of Cobram Estate Olives

In summary, while we are somewhat encouraged by Cobram Estate Olives reinvesting in its own business, we are aware that returns are diminishing. And over the past year, the stock has fallen 21%, so the market doesn’t seem too optimistic that these trends will strengthen anytime soon. Overall, the inherent tendencies aren’t typical of multi-baggers, so if that’s what you’re looking for, we think you might have better luck elsewhere.

Since virtually every business faces risks, it’s worth knowing about them, and we’ve spotted 2 warning signs for Cobram Estate Olives (including 1 not to be overlooked!) that you should know.

Although Cobram Estate Olives does not generate the highest yield, check out this free list of companies that achieve high returns on equity with strong balance sheets.

Feedback on this article? Concerned about content? Get in touch with us directly. You can also email the editorial team (at) Simplywallst.com.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.

Join a Paid User Research Session
You will receive a $30 Amazon Gift Card for 1 hour of your time while helping us create better investment tools for individual investors like you. register here

The Minneapolis-based healthcare private equity firm is on Inc.’s annual list. of the best private equity and venture capital firms that successfully support entrepreneurs

MINNEAPOLIS, October 13, 2022–(BUSINESS WIRE)–Healthcare private equity firm TT Capital Partners (TTCP) today announced that it has been named to the 2022 Founder Friendly Investor List of Inc. Inc.’s fourth annual Founder-Friendly Investors list, formerly known as the Private Equity 50, honors top private equity and venture capital firms that successfully support entrepreneurs.

This press release is multimedia. View the full press release here: https://www.businesswire.com/news/home/20221003006058/en/

(Photo: BusinessWire)

The 2022 list recognizes 184 companies that entrepreneurs partner with and trust because they receive the financial support they need to drive growth. All 184 have remained actively involved in the companies in which they invest.

“To fully invest in an entrepreneur and their innovative vision involves much more than financial investment. By developing relationships with entrepreneurs and supporting them over the long term, these private equity firms are more than investors, they are partners,” said Scott Omelianuk, editor of Inc. media.

“I founded this company over a decade ago with a clear vision to create meaningful connections with founders and business owners,” said Kevin Green, Executive Chairman and Partner of TTCP. “This vision has been an important part of our legacy from the start, and we’ve built a business and a team that’s focused on this idea of ​​connecting and adding value. I’m so proud of what our team has achieved. accomplished and honored to see our vision realized in this recognition.”

Dawn Owens, CEO and Partner of TTCP, added: “Our company has been purpose-built to be a value-added investor, providing not only capital, but also deep market intelligence, ongoing operational expertise and access to an extensive industry network to help our businesses grow and to help our founders realize their visions.”

The story continues

“From the first time I met them, TTCP impressed me with their deep industry knowledge and extensive relationships,” said David Hines, Founder of ConsumerMedical, a leading clinical advocacy and medical opinion company. expert in which TTCP invested in 2015. the investment, TTCP has supported the rapid growth of ConsumerMedical and the company’s revenues have increased by more than 450% in six years. In 2021, TTCP orchestrated the acquisition of ConsumerMedical by Alight Solutions.

“In the six years we have worked together, the TTCP team has always been available to step in and provide thoughtful advice and support,” Hines added. “After nearly 15 years as an independent, startup company, it was a great decision for us to raise capital and bring in a partner. Partnering with TT Capital Partners was a great decision for me and for ConsumerMedical, and I would make the same decision again today.”

To compile the 2022 list of Founder-Friendly Investors, Inc., we went straight to the source: entrepreneurs who tapped into private equity and venture capital firms. The founders completed a questionnaire about their experiences partnering with private equity and venture capital firms and shared data on how their businesses grew during those partnerships.

Introduced in 2019, the Founder-Friendly Private Equity Firms list has quickly established itself as one of Inc.’s most resourceful franchises. It has become a go-to guide for entrepreneurs who want to grow their business while maintaining a stake. The October 2022 issue of Inc. magazine is available online and on newsstands now. To see the full list, go to: https://www.inc.com/founder-friendly-investors/2022

About Inc.

The World’s Most Trusted Business Media Brand, Inc. gives entrepreneurs the knowledge, tools, connections and community they need to build great businesses. Its award-winning cross-platform content reaches over 50 million people every month across a variety of channels, including websites, newsletters, social media, podcasts and print. Its prestigious Inc. 5000 list, produced annually since 1982, analyzes company data to recognize the fastest growing private companies in the United States. The global recognition that comes with inclusion in the 5000 gives founders of top companies the opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 conference is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit www.inc.com.

About the TTCP

TT Capital Partners (TTCP) is a value-added healthcare investor that provides capital, expertise and insight to healthcare technology and services companies that have the potential to become market leaders. With an exclusive focus on healthcare, its extensive industry network and extensive investment and operating experience, TTCP has invested in some of the most dynamic companies innovating and disrupting the way healthcare is delivered, managed and consumed. To learn more, visit www.TTCapitalPartners.com.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20221003006058/en/

contacts

Becky Gauerke
bgauerke@ttcapitalpartners.com